Cancer Genetics postpones second IPO attempt

By
A A A

Cancer Genetics, which offers personalized genomic tests to improve the diagnosis and treatment of cancer, postponed its IPO on Thursday. The company originally filed for an IPO in December 2011 and attempted to go public in May at a $112 million valuation.  After postponing its original IPO effort, the company refiled for a deal that would value the company at $79 million in October. Ultimately, the company further slashed the deal, revising terms to value the company at $65 million, before postponing.

The Rutherford, NJ-based company was founded in 1999 and booked $4 million in sales for the 12 months ended 9/30/2012. Aegis Capital was set to be the sole bookrunner on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: CGIX

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

100%

Most Active by Volume

113,590,482
  • $14.98 ▼ 1.77%
57,689,941
  • $94.67 ▼ 0.37%
51,501,990
  • $3.31 ▼ 2.07%
46,645,770
  • $96.13 ▲ 0.55%
42,212,567
  • $72.36 ▼ 0.40%
39,428,076
  • $25.35 ▲ 0.80%
36,799,747
    $37 unch
36,459,390
  • $44.13 ▼ 2.35%
As of 8/1/2014, 04:03 PM